NASDAQ: EVGN
Evogene Ltd Earnings Dates, Reports, Calls

Evogene earnings were -$15.2M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest EVGN earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$2.6M, down 705.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EVGN reported annual earnings of -$16.5M, with -31% growth.

EVGN earnings history

Current Revenue
$6.8M
Current Earnings
-$15.2M
Current Profit Margin
-224.8%

EVGN Return on Equity

Current Company
N/A
Current Industry
-60.2%
Current Market
31.5%

EVGN undefined

Current Company
-39.2%
Current Industry
-2.5%
EVGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when EVGN announces earnings.

EVGN undefined

Current Company
-61.8%
Current Industry
5.8%
EVGN's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EVGN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
EVGN-$9.15M-$15.21MN/A-$2.43
KPRX-$9.77M-$12.05MN/A-$3.01
CYCC-$7.77M-$8.35MN/A-$15.20
CAPSN/AN/AN/AN/A
MBRX-$23.10M-$23.23MN/A-$4.73

Evogene Earnings Reports & History FAQ

What were Evogene's earnings last quarter?

On EVGN's earnings call on Invalid Date, Evogene (NASDAQ: EVGN) reported Q1 2025 earnings per share (EPS) of -$0.38, up 50% year over year. Total EVGN earnings for the quarter were -$2.59 million. In the same quarter last year, Evogene's earnings per share (EPS) was -$0.76.

If you're new to stock investing, here's how to buy Evogene stock.

Is Evogene profitable or losing money?

As of the last Evogene earnings report, Evogene is currently losing money. Evogene's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$15.21 million, a 29.16% decrease year over year.

What was EVGN's earnings growth in the past year?

As of Evogene's earnings date in Invalid Date, Evogene's earnings has grown year over year. EVGN earnings in the past year totalled -$15.21 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.